Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 16 unusual trades.
Delving into the details, we found 56% of traders were bullish, while 43% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $316,425, and 11 were calls, valued at $549,883.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $35.0 for Pfizer over the recent three months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer’s options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer’s substantial trades, within a strike price spectrum from $20.0 to $35.0 over the preceding 30 days.
Pfizer Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | PUT | SWEEP | BEARISH | 05/17/24 | $35.00 | $103.1K | 56 | 0 |
| PFE | CALL | SWEEP | BULLISH | 01/19/24 | $30.00 | $74.7K | 8.7K | 2.6K |
| PFE | CALL | SWEEP | NEUTRAL | 01/17/25 | $35.00 | $69.4K | 30.1K | 3.5K |
| PFE | CALL | SWEEP | BULLISH | 12/15/23 | $30.00 | $66.2K | 4.0K | 1.4K |
| PFE | PUT | SWEEP | BULLISH | 01/17/25 | $20.00 | $61.0K | 2.3K | 0 |
About Pfizer
Pfizer is one of the world’s largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Pfizer
- With a volume of 8,897,055, the price of PFE is up 0.38% at $29.09.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 77 days.
What The Experts Say On Pfizer
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $36.2.
- Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Pfizer, targeting a price of $35.
- Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Pfizer, targeting a price of $37.
- An analyst from Truist Securities persists with their Buy rating on Pfizer, maintaining a target price of $42.
- An analyst from UBS downgraded its action to Neutral with a price target of $34.
- Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Pfizer with a target price of $33.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.
